Jayanth Sridhar, MD, and Samuel Minaker, MD, MSc, FRCSC, review the disconnect between retreatment thresholds used in clinical trials versus what most retina specialists tolerate in real-world clinical practice.
Fluid Tolerance: Clinical Trials vs Real World
Media formats available:
Details
Presenters
Download Workbook
Grantor Statement
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Identify key risk factors and biomarkers that aid early detection and diagnosis of nAMD
- Analyze factors that prevent translation of nAMD clinical trial treatment efficacy into real-world treatment effectiveness
- Evaluate how advances in nAMD treatments could improve real-world patient outcomes
- Debate the clinical significance of different measures of treatment efficacy in nAMD and their real-world utility
- Discuss key considerations that may influence the selection, timing, and execution of treatment plans for patients with nAMD
Accreditation and Credit Designation Statements
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 0.25 AMA PRA Category Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Faculty
Samuel Minaker, MD,MSc, FRCSC
Rush University Medical Center
Illinois Retina Associates
Chicago, IL
Jayanth Sridhar, MD
Chief of Ophthalmology
Olive View Medical Center
Los Angeles, CADisclosure of Relevant Financial Relationships
DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence , it is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.
Samuel Minaker, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Genentech, Alimera Sciences, Apellis Pharmaceuticals, and Astellas Pharmaceuticals. Common Stock: Aldeyra Therapeutics.
Jayanth Sridhar, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Alimera Sciences, Apellis Pharmaceuticals, Eyepoint Pharmaceuticals, Genentech, Iveric Bio, and Regeneron. Speaker’s Bureau: Genentech and Regeneron.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Fluid Tolerance Clinical Trials vs Real World
Show more
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Christina Y. Weng, MD, MBA, FASRS
Mark T. Dunbar, OD, FAAO
David A. Eichenbaum, MD, FAAO
Jaclyn Garlich, OD, FAAO
Mohammad R. Rafieetary, OD, FAAO, FORS, ABO
Sunir J. Garg, MD, FACS, FASRS
Charles C. Wykoff, MD, PhD, FACS
Sunir J. Garg, MD, FACS, FASRS
Charles C. Wykoff, MD, PhD, FACS
- CME/CE Broadcast Replay
The Comanagement Plan: Elevating Retinal Care Through Unified Vision
1.00 creditSunir J. Garg, MD, FACS, FASRS
John W. Kitchens, MD
Sara LeMay, OD
Charles C. Wykoff, MD, PhD, FACS
